NCT06820970 CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
| NCT ID | NCT06820970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henan Institute of Cardiovascular Epidemiology |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,000 participants in total. It began in 2025-08-01 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can reduce cardiovascular adverse events in patients with incomplete revascularization of coronary artery disease.
Eligibility Criteria
Inclusion Criteria: * 1\) Age ≥18 years old * 2\) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \< 0.80) * 3\) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.); Exclusion Criteria: * Age \< 18 years old * Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \< 30% * Creatinine clearance \<15 mL/min (or eGFR \< 15 mL/min/1.73m²), or requires dialysis * Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc. * Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs) * Poorly controlled hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg) * Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal * Unexplained CK \> 5 times the upper limit of normal, or elevated CK due to known muscle disease * Planned or anticipated cardiac surgery or revascularization before randomization * History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years) * Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis * Hearing impairment, unable to undergo mindfulness therapy * Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug * Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases) * Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study * History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney) * Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study * As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
Contact & Investigator
Muwei LI, MD
STUDY CHAIR
Fuwai Central China of Cardiovascular Hospital
Frequently Asked Questions
Who can join the NCT06820970 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06820970 currently recruiting?
Yes, NCT06820970 is actively recruiting participants. Contact the research team at xinyiguoquan@163.com for enrollment information.
Where is the NCT06820970 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT06820970 clinical trial?
NCT06820970 is sponsored by Henan Institute of Cardiovascular Epidemiology. The principal investigator is Muwei LI, MD at Fuwai Central China of Cardiovascular Hospital. The trial plans to enroll 2,000 participants.